Adamas Pharmaceuticals (NASDAQ: ADMS) received a Buy rating and a $45 price target from H.C. Wainwright analyst Ram Selvaraju today. The company’s shares closed on Friday at $27.06.
Selvaraju commented:
“Valuation methodology, risks and uncertainties. We have utilized a discounted cash flow (DCF)-based approach to derive a composite valuation assessment of Adamas, which ascribes value to the company’s two principal product opportunities— GOCOVRI and ADS-5102—while also accounting for the token value provided by the royalty stream from Allergan plc on two other controlled-release products, for treatment of moderate-to-severe Alzheimer’s disease (AD).”
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.2% and a 44.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Adamas Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $49.75.
See today’s analyst top recommended stocks >>
Based on Adamas Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $34.97 million. In comparison, last year the company had a GAAP net loss of $20.75 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adamas Pharmaceuticals, Inc. is a pharmaceutical company, which engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products includes ADS-5012, ADS-4101, and Namenda XR. The ADS-5102 is a treatment for levodopa-induced dyskinesia in patients with Parkinson’s disease.
